Journal article
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
Abstract
BackgroundThe phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38). The rate of complete remission (CR) was 19.2% in the glasdegib + LDAC arm versus 2.6% in the LDAC arm (P = 0.015).MethodsThis post hoc …
Authors
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA
Journal
Journal of Hematology & Oncology, Vol. 13, No. 1,
Publisher
Springer Nature
Publication Date
December 2020
DOI
10.1186/s13045-020-00929-8
ISSN
1756-8722
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesBlood TransfusionCause of DeathClinical Trials, Phase II as TopicCombined Modality TherapyCytarabineFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiddle AgedMolecular Targeted TherapyMulticenter Studies as TopicPhenylurea CompoundsRandomized Controlled Trials as TopicRemission InductionTreatment Outcome